At Tres Alchemix, we specialise in unraveling the complexity of the human body by harnessing the combined power of quantum-level chemical calculations and multi-omics AI. Our platforms provide highly accurate predictions of molecular behaviour, including chemical-protein interactions, pharmacokinetics and pharmacodynamics, offering unparalleled insights into the complex dynamics of drugs within the body. This cutting-edge technology forms the foundation of our way towards a holistic in silico human model, which will enable us to explore the root causes of various diseases and drive the development of novel therapeutics.
Founded in 2023 in Fukuoka, Japan, we have since established our research and development hub in Oxford, UK. With a commitment to innovation and collaboration, our multidisciplinary team is consistently pushing the boundaries of pharmaceutical research.
Company Details
- Employees
- 3
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.tresalchemix.com
- Keywords
- Frankfurt.
Tres Alchemix Questions
Tres Alchemix's website is https://www.tresalchemix.com
Tres Alchemix's LinkedIn profile is https://www.linkedin.com/company/tres-alchemix
Tres Alchemix has
3 employees.
View email and phone details for 3
employees at Tres Alchemix.
Tres Alchemix's industry is
Biotechnology Research
Tres Alchemix's top competitors are
Fujiya Group,
Quintin Hogg Trust,
Biospire,
Multus,
Global Bio Fund,
Neudio,
The Bow Foodbank Ltd,
Hakuhodo Germany,
Trialex,
Alchemix.
Tres Alchemix's categories are Biotechnology Research
